|
Variable
|
Mortality from OC
|
Mortality from other causes
|
|---|
|
Group size
|
Deaths
|
HR
|
(95% CI)
|
Deaths
|
HR
|
(95% CI)
|
|---|
|
Year of diagnosis
|
|
1998─2002
|
115
|
84
|
1.00
|
Ref.
|
13
|
1.00
|
Ref.
|
|
2003─2007
|
149
|
106
|
1.17
|
(0.86–1.59)
|
12
|
1.16
|
(0.45–2.99)
|
|
2008─2011
|
157
|
86
|
0.97
|
(0.69–1.37)
|
9
|
1.13
|
(0.39–3.27)
|
|
Age at diagnosis (years)
|
|
42─59
|
59
|
30
|
0.67
|
(0.44–1.04)
|
1
|
0.18
|
(0.02–1.53)
|
|
60─69
|
132
|
76
|
1.00
|
Ref.
|
9
|
1.00
|
Ref.
|
|
70─79
|
160
|
120
|
1.53
|
(1.14–2.05)
|
14
|
2.49
|
(1.03–6.05)
|
|
80─92
|
70
|
50
|
2.88
|
(1.98–4.20)
|
10
|
5.40
|
(1.99–14.65)
|
|
Duration of diabetes (years)
|
|
0.5─ < 3
|
103
|
61
|
1.00
|
Ref.
|
11
|
1.00
|
Ref.
|
|
3─ < 6
|
100
|
70
|
1.31
|
(0.91–1.90)
|
3
|
0.35
|
(0.09–1.36)
|
|
6─ < 12
|
148
|
101
|
1.15
|
(0.81–1.63)
|
11
|
0.88
|
(0.34–2.27)
|
|
12─ < 34
|
70
|
44
|
0.98
|
(0.61–1.57)
|
9
|
1.20
|
(0.42–3.44)
|
|
Stage
|
|
Local
|
52
|
9
|
1.00
|
Ref.
|
9
|
1.00
|
Ref.
|
|
Advanced
|
330
|
256
|
9.05
|
(4.60–17.82)
|
19
|
0.80
|
(0.32–2.01)
|
|
Unknown
|
39
|
11
|
1.60
|
(0.66–3.89)
|
6
|
1.01
|
(0.32–3.23)
|
|
Pre-diagnostic statin use
|
|
No
|
235
|
162
|
1.00
|
Ref.
|
20
|
1.00
|
Ref.
|
|
Yes
|
186
|
114
|
0.72
|
(0.56–0.93)
|
14
|
0.66
|
(0.30–1.43)
|
|
Pre-diagnostic ADM group
|
|
Metformin
|
77
|
46
|
1.15
|
(0.74–1.79)
|
5
|
1.85
|
(0.44–7.73)
|
|
Othera
|
58
|
44
|
1.00
|
Ref.
|
4
|
1.00
|
Ref.
|
|
Metformin and othera
|
100
|
67
|
1.21
|
(0.82–1.80)
|
6
|
1.19
|
(0.32–4.38)
|
|
Insulin
|
82
|
59
|
1.49
|
(0.96–2.30)
|
7
|
1.61
|
(0.42–6.18)
|
|
None
|
104
|
60
|
0.69
|
(0.46–1.03)
|
12
|
1.48
|
(0.46–4.78)
|
- All HRs were adjusted for the other factors in this table
- aother oral antidiabetic medication
- OC Ovarian cancer, HR Hazard ratio, 95% CI 95% confidence interval
